View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 11, 2019

Immunicum begins ilixadencel combination therapy in ILIAD trial

Pharmaceutical company Immunicum has started dosing patients in the Phase Ib/II ILIAD clinical trial of ilixadencel and checkpoint inhibitors (CPIs) combination to treat cancer.

Pharmaceutical company Immunicum has started dosing patients in the Phase Ib/II ILIAD clinical trial of ilixadencel and checkpoint inhibitors (CPIs) combination to treat cancer.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Ilixadencel is a cell therapy candidate designed as an off-the-shelf cancer immune primer using activated allogeneic dendritic cells obtained from healthy blood donors.

Intratumoral injection of dendritic cells is said to produce an inflammatory response that causes tumour-specific activation of the patient’s cytotoxic T-cells.

The open-label, multicentre Phase Ib/II trial will assess the combination therapy’s safety and efficacy in patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) or gastric and gastroesophageal junction adenocarcinoma (GA/GEJ).

Immunicum chief medical officer Peter Suenaert said: “The start of the ILIAD clinical trial is a positive and important step in the development of ilixadencel, testing its ability to prime a patient’s immune system to fight the cancer.

“This study will give us the opportunity to further evaluate its potential as a backbone component in combination therapies to treat solid tumors.”

“This study will give us the opportunity to further evaluate its potential as a backbone component in combination therapies to treat solid tumors, and we look forward to exploring the synergistic effects of the immune activity of ilixadencel together with CPIs.”

The Phase Ib part of ILIAD will evaluate the safety and determine the optimal dose and schedule of ilixadencel in combination with the standard dose of CPI pembrolizumab (Keytruda) in 21 patients.

This portion will be carried out at clinical sites across the US.

The trial’s Phase II part will involve three randomised, controlled studies to investigate the safety and efficacy of ilixadencel plus CPI combination in a total of up to 150 patients in the US and Europe.

In NSCLC patients, ilixadencel will be combined with pembrolizumab (Keytruda), while HNSCC and GA/GEJ patients will be administered with ilixadencel and avelumab (Bavencio) combination.

Merck and Pfizer will supply Keytruda and Bavencio, respectively, under a collaboration agreement.

Sweden-based Immunicum secured protocol approval from the US Food and Drug Administration (FDA) for the ILIAD trial in July last year.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena